Trial Profile
A Prospective Phase II Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients Aged 61 Years And Older, With Classical Hodgkin Lymphoma And Coexisting Medical Conditions.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Vinblastine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 14 Dec 2021 Results assessing safety and efficacy of nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 13 Aug 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 05 May 2021 Status changed from recruiting to active, no longer recruiting.